Alnylam and Merck Scuttle $120M-Plus RNAi Drug-Development Partnership | GenomeWeb
NEW YORK (GenomeWeb News) — Alnylam and Merck today said they have ended an ongoing RNAi drug-development alliance, and Alnylam has rescinded its IP grants related to any Merck development programs.
 
The deal was worth more than $120 million to Alnylam and ended on a mutually agreed upon note. The companies did not elaborate.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.